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a Comment to a Summary Report of the First
PET/MRI Workshop in Tuebingen in 2012
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UCLA, 10833 Le Conte Avenue, Room 2-222 CHS, Los Angeles, CA, 90095-1782, USA
A recent volume of Molecular Imaging and Biologyincludes a report of a workshop on preclinical and
clinical positron emission tomography (PET)/magnetic reso-
nance imaging (MRI). The workshop was prompted by the
emergence of integrated clinical PET/MRI systems [1] and
provided a forum for sharing initial experiences in the preclinical
and clinical applications of this technology. The authors correctly
point out that PET/MRI “must offer new areas of applications
exploiting the strengths of each technology” and, as such, should
not be in conﬂict with PET/computed tomography (CT).
The strength of PET imaging as the only mature clinical
molecular imaging tool is evident. Its critically important
role for initial and subsequent management decision in
cancer patients is undisputed [2]. At the same time, MRI is
emerging as a powerful tool to image biological processes
including tumor perfusion, oxygenation, metabolism, and
others (reviewed in [3, 4]). However, it is unknown whether
the combination of PET and MRI in integrated PET/MRI
systems improves patient management and outcome.
It is noteworthy that CT has remained the dominant force
in cancer imaging despite signiﬁcant expansion of MRI
capabilities (with the notable exception of brain tumor
imaging). The number of CT studies outnumbers that of
MRI by factors of 4, 12, 5.5, 7.9, and 4 in breast, colorectal,
lung cancer, non-Hodgkin lymphoma, and prostate cancer,
respectively [5]. Simple explanations are that CT is well
tested, safe, comparably inexpensive, easy to operate, and
useful for managing cancer patients. In fact, almost every
intervention contemplated in cancer patients (biopsy, sur-
gery, radiation therapy) requires the use of CT imaging.
While it is premature to offer an appraisal of the role of
clinical PET/MRI imaging, some theoretical advantages are
evident. First, PET/MRI exposes patients to much less
radiation than PET/CT. Second, MRI has been reported to
detect and stage some cancers with a higher accuracy than
CT. Finally, PET/MRI has the capability to obtain biolog-
ical, functional, and anatomical data near simultaneously.
However, some of these proposed advantages warrant a
critical examination. For instance, one well-publicized concern
about CT is the associated radiation exposure of patients [6].
While this concern is appropriate when CT imaging is used
inappropriately (for instance, for cancer screening), such risks
are greatly diminished for cancer patients with a limited life
expectancy [7]. Moreover, using different models, a more
recent analysis suggested that “risks of medical imaging at
effective doses below 50 mSv for single procedures or
100 mSv for multiple procedures over short time periods are
too low to be detectable and may be nonexistent” and that
“predictions of hypothetical cancer incidence and deaths in
patient populations exposed to such low doses are highly
speculative and should be discouraged” [8]. Nevertheless,
reduced radiation exposure through the use of PET/MRI rather
than PET/CT could be advantageous in “at risk” populations
such as children and women of childbearing age.
Reports have suggested that MRI is more accurate than
CT for several oncological indications including prostate
cancer, pancreatic cancer, primary or metastatic liver cancer,
bone metastasis, head and neck cancer, and others. However,
the evidence in support of this notion is hard to ﬁnd. For
instance, in pancreatic cancer, CT and MRI are equally
accurate, and the choice between modalities is frequently
determined by the level of expertise and availability of the
modality [9], and neither CT nor MRI detected vascular
invasion reliably [10]. A meta-analyses for lymph node
staging in head and neck cancer also failed to ﬁnd improved
accuracy of MRI over CT [11]. A meta-analysis in prostate
cancer revealed low accuracies for both MRI and CT
imaging [12]. However, using a lymph node-speciﬁc
contrast agent improved the accuracy of MRI over CT
[13]. In yet another meta-analysis, MRI and CT detected
liver metastases with a comparable accuracy, and both
tended to perform worse than 2-deoxy-2-[18F]ﬂuoro-D-
glucose (FDG) PET/CT [14]. The notable exception is theCorrespondence to: Johannes Czernin; e-mail: jczernin@mednet.ucla.edu
imaging of brain tumors for which MRI is clearly superior to
CT. Thus, there is little evidence that MRI exceeds the
accuracy of CT in any cancer other than brain tumors, and
there is even less evidence that MRI is cost-effective in any
setting including breast cancer [15] and pancreatic cancer
[16].
The ability to simultaneously acquire molecular, functional,
and anatomical information using PET/MRI has also been used
as a strong argument for the use of PET/MRI (Bailey et al.,
workshop report). Conceptually, this ability is intriguing if one
assumes that (a) biological processes change withinminutes and
(b) that therapeutic interventions elicit biological responses
within the time frame of a combined PET/MRI study. For
instance, tumor FDG uptake is relatively stable even if PET
measurements are repeated within up to 1 week [17]. Moreover,
MRI tumor perfusion measurements were reproducible within
20 % even when studies were performed 2–7 days apart [18].
The good reproducibility of PET and MRI measurements
over several days suggests that simultaneous measurements
may not be critically important for clinical application since
the processes under study appear to be fairly stable.
There is, however, a clear advantage for PET/MRI to
investigate, in research studies, molecular and functional
processes simultaneously. From these research studies, insights
might be gained that eventually could lead to important clinical
applications.
As proposed by PERCIST [19], early partial metabolic
tumor response is deﬁned as a decrease in tumor FDG uptake by
30 %. Reductions in FDG uptake become more signiﬁcant
when time is allowed for additional cycles of chemotherapy.
Since metabolic or functional tumor responses to treatment
require at least several days to be measurable, it is quite unlikely
that measurements of functional and molecular parameters are
required to determine such changes simultaneously. The
relative stability of metabolic and perfusion measurements from
PET and MRI is not surprising. It is highly unlikely that gene
expression, transcription, and translation, whether under base-
line condition or in response to treatment, are executed within
minutes or a few hours. Only such rapid changes in biological
processes would require simultaneous measurements.
Many cancer patients undergo MRI as their primary
imaging study in cancer. It clearly would be prudent to study
these patients with PET/MRI and determine whether the
integrated modality provides diagnostic, prognostic, or even
predictive beneﬁts over the individual imaging modalities.
MRI is a powerful imaging tool, and applications now
include, among others, anatomical whole body surveys as well
as measurements of metabolism, hemodynamics, vasculariza-
tion, tumor viability apoptosis, and others [4]. However, only
well-designed research studies will determine whether com-
bining PET and MRI in a single imaging device provides
incremental and translatable information that could not be
obtained by stand-alone systems.
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